Tetrabenazine and deutetrabenazine are the only small-molecule drugs approved by the Food and Drug Administration (FDA) and also in China to manage HD chorea.[91,92,93] modulating dopamine by selectively inhibiting vesicular monoamine transporter type 2 (VMAT2).[94] In addition to controlling the symptoms of chorea, several clinical trials (NCT04301726, NCT0471398) are also conducted to elucidate the efficacy of deutetrabenazine to control symptoms of dysphagia, functional speech and gait dynamics in HD patients, while no results have been published up to now. Here, SLC18A2 is linked to choreatic disease.